CCL2 and glioblastoma: Treatment of GBM cells with MSAB (24 h) increased CCL2 levels in the supernatants of GBM1 (p = 0.0175) and SF188 (p = 0.0036), while the supernatant of JHH520 (p = 0.0224) showed significantly reduced CCL2 levels (Figure 5C).